HUMA
HUMA
NASDAQ · Biotechnology

Humacyte Inc

$0.55
-0.01 (-1.81%)
As of Sep 28, 10:16 PM ET ·
Financial Highlights (FY 2026)
Revenue
3.53M
Net Income
-70,662,397
Gross Margin
-376.0%
Profit Margin
-2,003.6%
Rev Growth
+17.4%
D/E Ratio
20.86
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -376.0% -376.1% 41.4% 41.4%
Operating Margin -6,398.6% -5,758.8% 4.5% 4.7%
Profit Margin -2,003.6% -1,903.4% 3.2% 3.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.53M 3.01M 180.17M 139.91M
Gross Profit -13,276,005 -11,310,278 74.60M 57.93M
Operating Income -225,896,145 -173,203,723 8.07M 6.54M
Net Income -70,662,397 -54,179,721 5.71M 4.80M
Gross Margin -376.0% -376.1% 41.4% 41.4%
Operating Margin -6,398.6% -5,758.8% 4.5% 4.7%
Profit Margin -2,003.6% -1,903.4% 3.2% 3.4%
Rev Growth +17.4% +17.4% +21.8% +16.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 73.87M 73.87M 75.78M 80.20M
Total Equity 3.54M 3.54M 156.42M 129.75M
D/E Ratio 20.86 20.86 0.48 0.62
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -212,945,049 -172,344,348 9.37M 7.10M
Free Cash Flow — — 5.00M 3.87M